Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) for Oxcarbazepine Tablets USP, 150 mg, 300 mg and 600 mg, the company announced through an exchange filing.
Oxcarbazepine is used alone or with other medications to treat seizure disorders (epilepsy). The product will be manufactured at the group’s formulation manufacturing facility in Baddi, Himachal Pradesh (India).
Oxcarbazepine Tablets USP, 150 mg, 300 mg and 600 mg had annual sales of USD 105 mn in the United States (IQVIA MAT May 2023).
The group now has 374 approvals and has so far filed over 442 ANDAs since the commencement of the filing process in FY 2003-04.
VIDEO: Union Minister Amit Shah Praises Rajasthan CM Bhajan Lal Sharma For Strong Governance, Paper Leak SIT & Cooperative Reforms
IND vs ENG: Morne Morkel Bowls To Team India Batters As They Practice In Beckenham Ahead Of 4th Test; Video
Palghar Tragedy: 46-Year-Old Ola Driver Dies By Suicide After Consuming Poison In Nalasopara; Family Alleges Company Harassment
RCB Parade Stampede: Karnataka Govt Accepts Justice D'Cunha Report, Criminal Cases To Be Filed Against RCB, KSCA, Event Organisers
